Takeda's Orzeyful wins FDA approval as the first full-symptom narcolepsy type 1 drug, kicking off an orexin agonist race with Lilly and Alkermes close behind.
One of the most closely watched commercial drug races is now off and running, after Takeda snagged FDA approval of its orexin agonist to treat …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Takeda approval ushers in new wave of sleep drugs
Takeda gains FDA nod for first-in-class narcolepsy treatment Orzeyful
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
FDA Approves First-in-Class Narcolepsy Drug
Takeda’s narcolepsy drug approved by the FDA, seen as a boon for new class of treatments
FDA approves new drug for narcolepsy type 1 symptoms - UPI.com
China Beats U.S. in Approving Takeda’s Breakthrough Narcolepsy Drug
Svolta contro la narcolessia, negli Usa la prima cura che agisce sulla causa della malattia
Two FDA approvals — a new drug and a new vaccine
How Ozempic maker Novo Nordisk blew its lead -2-
